$135MSeries B, 11 June 2025
Series B to fund Phase 1/2 of lead Stargardt disease program SB-007 and expand its pipeline
- Amount
- $135M
- Stage
- Series B
- Announced
- 11 June 2025
- Lead
- EQT Life Sciences
- Other investors
- Sanofi Ventures, Roche Venture Fund, New Enterprise Associates, Novartis Venture Fund
- Use of funds
- Series B to fund Phase 1/2 of lead Stargardt disease program SB-007 and expand its pipeline
- Checked
- Announced by the company
- Sources
- SpliceBio raises $135M Series B splice.bio
SpliceBio raises $135M Series B techstartups.com
SpliceBio raises $135M Series B pulse2.com